Skip to main content
CVSA
NYSE Trade & Services

Covista 10-Q Details Q1 FY2027 Beat: Revenue $511.5M, EPS $1.95, Credit Losses Up

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Education Stocks · Consumer
Sentiment info
Positive
Importance info
7
Price
$134.66
Mkt Cap
$4.36B
52W Low
$86.97
52W High
$152.12
52W Position info
55% above low
Off High info
11% below high
Rel. Volume info
1.1× avg
Market data snapshot near publication time

CVSA sits 55% above its 52-week low of $86.97.

Summary

Covista's Q1 FY2027 10-Q confirms the earnings beat — $511.5 million revenue and $1.95 diluted EPS — while flagging a jump in credit-loss provisions to $22.4 million and 19,039 pending Borrower Defense claims.


Key Events · Earnings and Guidance · CVSA

  • Q1 Beat Confirmed in Full Statements

    Revenue of $511.5 million rose 10.7% and diluted EPS of $1.95 rose 16.8% from $1.67, with net income of $67.4 million.

  • Segment Mix: Walden and Med/Vet Lead

    Walden revenue grew 14.1% to $216.7 million and Medical and Veterinary adjusted operating income jumped 32.7% to $22.3 million; Chamberlain's adjusted operating margin fell to 13.9% from 14.3%.

  • Credit Loss Provision Nearly Doubles

    Provision for credit losses rose to $22.4 million from $14.9 million a year ago, lifting the allowance to $70.7 million against $305.6 million of gross accounts and financing receivables.

  • Cash Down on Debt Paydown and Buybacks

    Cash and equivalents fell to $222.2 million from $406.3 million after $163.0 million of revolver repayment and $81.0 million of share repurchases; operating cash flow was $114.3 million versus $130.6 million.


Analysis · CVSA · Trade & Services

The 10-Q fills in the numbers behind this morning's earnings release, and they confirm the beat: revenue of $511.5 million (+10.7%) and diluted EPS of $1.95 (+16.8%), with Walden (+14.1% revenue) and the medical/veterinary schools (adjusted operating income +32.7%) doing the heavy lifting while Chamberlain's adjusted operating margin slipped to 13.9% from 14.3%. Less cheerful is the credit book — provision for credit losses jumped to $22.4 million from $14.9 million a year ago and the allowance now stands at $70.7 million — and cash fell to $222.2 million from $406.3 million after $163.0 million of revolver repayment and $81.0 million of buybacks. The filing also quantifies the Borrower Defense exposure for the first time in this cycle: 19,039 claims across the five institutions, with the Department of Education resuming batches in August 2026 and no approvals or recoupment notices received to date.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, CVSA was trading at $134.66 on NYSE in the Trade & Services sector, with a market capitalization of approximately $4.4B. The 52-week trading range was $86.97 to $152.12. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CVSA - Latest Insights

CVSA
Oct 29, 2026, 4:16 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $134.66
Real-time Price: $117.53 info
Change: -$17.13 (-13%) info
Market Cap: $3.908B info
CVSA
Oct 29, 2026, 4:05 PM EDT
Source: BusinessWire
Importance Score:
8
Price at Filing: $128.76
Real-time Price: $117.53 info
Change: -$11.23 (-9%) info
Market Cap: $3.908B info
CVSA
Aug 06, 2026, 4:21 PM EDT
Filing Type: 10-K
Importance Score:
8
Price at Filing: $126.50
Real-time Price: $117.53 info
Change: -$8.97 (-7%) info
Market Cap: $3.908B info
CVSA
Aug 06, 2026, 4:19 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $126.50
Real-time Price: $117.53 info
Change: -$8.97 (-7%) info
Market Cap: $3.908B info
CVSA
Aug 06, 2026, 4:05 PM EDT
Source: BusinessWire
Importance Score:
8
Price at Filing: $125.32
Real-time Price: $117.53 info
Change: -$7.79 (-6%) info
Market Cap: $3.908B info